BiotechTube
UroMems

UroMems

Grenoble, France· Est.
uromems.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $30M

Overview

UroMems is a private, clinical-stage medical device company developing the UroActive® implant, a breakthrough automated treatment for stress urinary incontinence. The company leverages a proprietary MyoElectroMechanical Systems (MEMS) technology platform to create smart, active implants that can be adjusted remotely to meet individual patient needs. With over €90 million raised from notable European investors and a robust intellectual property portfolio, UroMems is positioned to address a significant unmet clinical need in a large and growing global market. The company is led by an experienced team of founders and industry veterans with deep expertise in urology, biomedical engineering, and medical device commercialization.

Urology

Technology Platform

Proprietary MyoElectroMechanical Systems (MEMS) platform integrating microelectronics and micromachining for smart, active implantable devices that can sense and respond automatically or via remote control.

Funding History

2
Total raised:$30M
Series B$20M
Series A$10M

Opportunities

UroMems operates in the large and growing global market for urinary incontinence devices, which is driven by an aging population.
Its automated UroActive® implant addresses significant drawbacks of current mechanical artificial sphincters, offering a potential paradigm shift in treatment that could command premium pricing and rapid adoption if clinical benefits are proven.
The proprietary MEMS platform also provides a foundation for future smart implants in urology and beyond.

Risk Factors

The company faces substantial regulatory risk in obtaining CE Mark and FDA approval for its novel active implantable device.
Clinical trial delays or failures, manufacturing scalability challenges, and the need to secure favorable reimbursement and drive surgeon adoption in a conservative market post-approval present significant hurdles to commercialization.

Competitive Landscape

UroMems' primary competition comes from established mechanical artificial urinary sphincters like Boston Scientific's AMS 800™ and male sling procedures. Its key differentiator is the automation and remote adjustability of its device, positioning it as a potential first-in-class smart implant. It may also face future competition from other companies developing next-generation neuromodulation or regenerative therapies for incontinence.

More companies in Digital Health & Biotech SaaS →More companies in France →